Related Experiment Video
Updated: Jul 19, 2026
Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus
Published on: March 6, 2019
Antithrombin for respiratory distress syndrome in preterm infants
D Bassler1, D Millar, B Schmidt
1McMaster University Medical Center, Department of Pediatrics/NICU, Room 4G40, 1200 Main Street West, Hamilton, Ontario, Canada. dirkbassler@hotmail.com
Insights
Antithrombin (AT) concentrate treatment for preterm infants with respiratory distress syndrome (RDS) did not decrease mortality and may increase harm. This review suggests AT concentrate is unlikely to benefit infants with RDS.
Area of Science:
- Neonatal Medicine
- Critical Care
- Pharmacology
Background:
- Acquired Antithrombin (AT) deficiency is common in preterm infants with respiratory distress syndrome (RDS).
- Hypothesized that AT concentrate may improve clinical outcomes in preterm infants with RDS.
Purpose of the Study:
- To determine if AT concentrate administration decreases mortality in preterm infants with RDS compared to placebo or no treatment.
Main Methods:
- Systematic review and meta-analysis of randomized controlled trials.
- Searched Cochrane Central Register, MEDLINE, EMBASE up to August 2006.
- Included 2 trials with 182 preterm infants (mean gestational age 28 weeks).
Main Results:
- No individual trial showed a significant difference in mortality.
- Pooled analysis favored control (RR 2.67, 95% CI 0.72-9.83) for early mortality.
- One trial stopped early due to increased deaths in the AT group (11.5% vs 3.3% mortality).
Conclusions:
- Preterm infants with RDS are unlikely to benefit from AT treatment.
- AT concentrate may potentially cause harm in this population.
Background:
Acquired Antithrombin (AT) deficiency is a common and prognostically important finding in sick preterm infants with respiratory distress syndrome (RDS). It has been hypothesised that AT concentrate may improve clinical outcomes in preterm infants with RDS.
Objectives:
To determine whether the administration of AT concentrate decreases mortality in preterm infants with RDS compared with placebo or no treatment.
Search Strategy:
An electronic literature search in the Cochrane Central Register of Controlled Trials, MEDLINE, and EMBASE in August 2006 was performed. No language restriction was applied. References from identified studies were cross-checked for possible additional studies. Experts in the field and pharmaceutical companies were contacted for unpublished data. Abstracts of the American Society of Pediatric Research and European Society of Pediatric Research meetings (1983-2005) were searched and authors of relevant studies were contacted to obtain additional information.
Selection Criteria:
Randomized controlled trials comparing any dose and duration of AT therapy with placebo or no treatment in preterm infants with RDS.
Data Collection And Analysis:
Two reviewers independently extracted data from included studies regarding mortality, intraventricular hemorrhage, mechanical ventilation, and other reported events in the clinical course of the patients. Data for similar outcomes were combined where appropriate, using a fixed-effects model in MetaView 4.2 (Update Software).
Main Results:
Two trials consisting of 182 preterm infants, fulfilled the inclusion criteria. Mean gestational age of patients included was 28 weeks. In one trial, patients had to be intubated and ventilated for RDS to be eligible for the study. In the other trial, RDS was not mentioned as an inclusion criteria, however the vast majority of infants in the study received surfactant. No individual trial showed a significant difference in mortality. One of the trials was stopped early because of an increase in deaths in the AT group. The pooled analysis for mortality within the first week of life showed a typical relative risk of 2.67 (95% CI 0.72-9.83) in favour of the control group. Only the trial that was stopped early followed the infants long enough to report neonatal mortality. This trial reported 7 deaths (11.5%) in the AT group and two deaths (3.3%) in the placebo group within 28 days of life. Secondary outcomes included days of mechanical ventilation and supplemental oxygen which were only reported in 1 trial. Both outcomes were in favour of the control group and statistically significant (p < 0.05).
Authors' Conclusions:
Preterm infants with RDS are unlikely to benefit from AT treatment and may be harmed.
Related Concept Videos
01:29Respiratory Syncytial Virus Disease
01:29Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
01:26Endoscopic Studies II: Thoracocentesis
Description
Excess pleural fluid or air may accumulate in some respiratory disorders in the thoracic cavity. To treat pleural effusion, a physician conducts thoracentesis by carefully piercing the chest wall and entering...
01:19Respiratory Assessment: Purpose and Indications
Objectives and Importance:
The primary goal of respiratory assessment is to evaluate patients at early risk of clinical deterioration. Since respiratory distress often precedes other signs of declining health, breathing patterns and sounds become a...
01:23Acute Respiratory Failure-IV
01:05Breathing